ARTICLE | Clinical News
Yervoy ipilimumab: Phase III discontinued
November 2, 2015 8:00 AM UTC
Bristol-Myers discontinued the double-blind, international Phase III Study -104 in about 920 patients with stage IV/recurrent NSCLC after Yervoy plus paclitaxel and carboplatin missed the primary endp...